Profund Advisors’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Profund Advisors's PTGX Position: Q3 2026 in Review
Profund Advisors increased its Protagonist Therapeutics (PTGX) stake by 10% in Q3 2026, buying an estimated $236K and bringing the position to 17,772 shares worth $2.5M. The position accounts for 0.07% of the portfolio, ranked #157.
Profund Advisors first reported a position in PTGX in Q1 2023 and has held it in 15 quarters since. 88 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Profund Advisors held 17,772 shares of Protagonist Therapeutics worth $2.5M as of Q3 2026.
- Profund Advisors bought 1,654 Protagonist Therapeutics shares in Q3 2026, an estimated $236K.
- Protagonist Therapeutics made up 0.07% of Profund Advisors's portfolio in Q3 2026, its #157 holding.
- Profund Advisors first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 15 quarters since.
- 88 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.